InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

Research didn’t obtain major endpoint of outlined enchancment on customary impairment scale
InVivo to judge full knowledge set and strategic choices for the corporate

March 9, 2023

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a analysis and clinical-stage biomaterials and biotechnology firm with a deal with the therapy of spinal cord accidents (SCI), right this moment introduced topline outcomes from the corporate’s INSPIRE 2.0 examine, which was designed to judge the protection and possible advantage of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based system in growth for sufferers with acute SCI. The examine didn’t meet its major endpoint, which was assessed by the proportion of handled sufferers reaching an enchancment of a minimum of one American Spinal Damage Affiliation (ASIA) Impairment Scale (“AIS”) grade at six months post-scaffold implantation, versus a management group that acquired customary of care surgical procedure.

“We’re disenchanted by the result of this examine as therapies for spinal cord injury are so urgently wanted and we all know many within the SCI affected person and advocate neighborhood wait in hope for therapeutic choices. Now we have rigorously pursued the science and imagine that, upon full evaluation, the INSPIRE 2.0 knowledge set will present a major addition to the medical literature across the therapy of SCI,” mentioned Richard Toselli, M.D., InVivo’s President and Chief Govt Officer. “I lengthen our deepest due to our sufferers and medical websites who’ve supported InVivo’s work to deliver our science to sufferers, and the InVivo group who’ve tirelessly pursued our mission.”

InVivo administration will conduct a full evaluation of the examine knowledge set and plans to share its findings in full in a peer-reviewed medical venue at a later date. The corporate may also consider its strategic choices and supply an replace on company course when acceptable.

About InVivo Therapeutics

InVivo Therapeutics is a clinical-stage biomaterials and biotechnology firm with a deal with the therapy of spinal cord accidents. The corporate was based in 2005 with proprietary know-how co-invented by Robert Langer, Sc.D., and Joseph P. Vacanti, M.D. InVivo is headquartered in Cambridge, MA. For extra particulars, go to www.invivotherapeutics.com.

Secure Harbor Assertion

Any statements contained on this press launch that don’t describe historic details might represent forward-looking statements inside the which means of the federal securities legal guidelines. These statements could be recognized by phrases corresponding to “imagine,” “anticipate,” “intend,” “estimate,” “will,” “might,” “ought to,” “anticipate” and related expressions, and embody statements concerning the corporate’s evaluation of the total INSPIRE 2.0 knowledge set and analysis of strategic choices. Any forward-looking statements contained herein are primarily based on present expectations and are topic to a lot of dangers and uncertainties. Components that would trigger precise future outcomes to vary materially from present expectations embody, however are usually not restricted to, dangers and uncertainties regarding its means to establish strategic choices and different dangers recognized and described in additional element within the firm’s Annual Report on Type 10-Ok for the yr ended December 31, 2022, and in different filings that the corporate might make with the Securities and Trade Fee sooner or later. The corporate doesn’t undertake to replace these forward-looking statements.